Improved metabolic profiles in insulin-treated diabetic patients given an alpha-glucosidehydrolase inhibitor

Br Med J. 1979 Jan 27;1(6158):220-1. doi: 10.1136/bmj.1.6158.220.

Abstract

An alpha-glucosidehydrolase inhibitor (acarbose; BAY g 5421) taken with food was compared with dummy tablets in seven insulin-treated diabetic patients over eight-hour periods that included breakfast, lunch, and two snacks. Acarbose diminished the postprandial increases in blood glucose, lactate, and pyruvate concentrations and may therefore be of value in the management of insulin-dependent diabetes.

Publication types

  • Clinical Trial
  • Controlled Clinical Trial

MeSH terms

  • Administration, Oral
  • Adult
  • Aged
  • Blood Glucose / analysis
  • Cyclohexanols / administration & dosage
  • Cyclohexanols / pharmacology*
  • Cyclohexanols / therapeutic use
  • Diabetes Mellitus / blood*
  • Diabetes Mellitus / drug therapy
  • Female
  • Food
  • Glucosidases / antagonists & inhibitors*
  • Glycoside Hydrolase Inhibitors*
  • Humans
  • Insulin / therapeutic use
  • Lactates / blood
  • Male
  • Middle Aged
  • Oligosaccharides / pharmacology*
  • Pyruvates / blood
  • Trisaccharides / administration & dosage
  • Trisaccharides / pharmacology*
  • Trisaccharides / therapeutic use

Substances

  • Blood Glucose
  • Cyclohexanols
  • Glycoside Hydrolase Inhibitors
  • Insulin
  • Lactates
  • Oligosaccharides
  • Pyruvates
  • Trisaccharides
  • Glucosidases